(Q46024830)

English

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

scientific article published on 4 May 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. (English)

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

0 references

1 reference

based on heuristic

inferred from title

8

object named as

Michael Weller

1 reference

Europe PubMed Central

18 December 2017

7

object named as

Wolfgang Wick

1 reference

Europe PubMed Central

18 December 2017

Joachim Steinbach

9

object named as

Joachim P Steinbach

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

Michael W Ronellenfitsch

1

object named as

Michael W Ronellenfitsch

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

Felix Tritschler

5

object named as

Felix Tritschler

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

author name string

Daniel P Brucker

2

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

Michael C Burger

3

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

Stefan Wolking

4

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

Johannes Rieger

6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

language of work or name

0 references

publication date

4 May 2009

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

132

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

Pt 6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

1509-1522

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Hypoxia in cancer cell metabolism and pH regulation

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

A system for stable expression of short interfering RNAs in mammalian cells

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

EGFR signals to mTOR through PKC and independently of Akt in glioma

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Regulation of eIF-4E BP1 phosphorylation by mTOR.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Upstream and downstream of mTOR

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Mechanisms of resistance to rapamycins

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Genetic pathways to glioblastoma: a population-based study

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Activation of Akt predicts poor outcome in neuroblastoma

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Mechanisms of apoptosis in central nervous system tumors: application to theory

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Survival of cancer cells is maintained by EGFR independent of its kinase activity

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

TOR signaling in growth and metabolism

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWP093

21 January 2018

Identifiers

10.1093/BRAIN/AWP093

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19416948

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46024830&oldid=1859604420"